The approach to cancer treatment reveals distinct differences between the United States and Europe . In the America, treatment is often highly fragmented , with a greater reliance on personal insurance and a propensity towards aggressive therapeutic strategies, frequently at a higher expense . Unlike, Transatlantic systems typically present univers

Significant variations exist when analyzing cancer care systems in the US and Western Europe. The US model, generally characterized by private insurance and a priority on innovation, often leads to rapid introduction of novel therapies, albeit at a significantly greater cost. On the other hand, Continental systems frequently rely on public funding